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A B S T R A C T
People with chronic conditions, such as epilepsy, are at a high risk for depression; however depression is
often under-recognized and undertreated. Depression scales, including one speciﬁc to people with
epilepsy, have been used for screening in this population, although none have been assessed with Rasch
measurement theory. This study used Rasch analyses in order to evaluate and compare the psychometric
properties of the modiﬁed Beck Depression Inventory, the Patient Health Questionnaire, and the
Neurological Disorders Depression Inventory for Epilepsy in a sample of people with epilepsy and
depression who participated in an intervention designed to reduce depressive symptoms. A secondary
purpose was to assess item functioning across time. The sample includes 44 participants in the Project
UPLIFT program who completed the assessments before and after taking part in the intervention. Results
of the Rasch analysis indicate that the three depression scales functioned as intended. There was good
overall targeting between the items and the sample, acceptable model-data ﬁt, and good reliability of
separation for persons, items, and time. The participants experienced a signiﬁcant decrease in depressive
symptoms from pretest to posttest. This study illustrates the value of using model-based measurement
with the Rasch model to combine items across the three depression scales. It also demonstrates an
approach for analyzing and evaluating the results of small scale intervention programs, such as the
UPLIFT program.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
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Depression among people with chronic conditions, including
epilepsy, is recognized to be a major concern. Depression is the
most common psychiatric disorder among people with epilepsy
(PWE) and is negatively associated with heath quality of life.1,2
Additionally, depression often is not recognized or diagnosed
among PWE.3 As more attention has been brought to this problem,
several standard depression measures have been tested for
reliability and validity as screening measures in this population,
including a measure speciﬁcally designed for people with epilepsy.
The Beck Depression Inventory (BDI),4 Center for Epidemiologi-
cal Study of Depression scale (CES-D),5 Patient Health Question-
naire (PHQ-9),6,7 and Neurological Disorders Depression Inventory
for Epilepsy (NDDI-E)8 have all been used to assess depressive
symptoms among people with epilepsy.9–11 Jones and colleagues10
found that both the BDI and CES-D were able to identify depression* Corresponding author at: Rollins School of Public Health, Emory University,
1518 Clifton Rd., GCR Room 544, Atlanta, GA 30322, United States.
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http://dx.doi.org/10.1016/j.seizure.2012.04.009with good speciﬁcity and sensitivity in a sample of people with
epilepsy who attended a tertiary outpatient clinic. Similar results
were found with the PHQ-9.11 The NDDI-E was speciﬁcally
designed to measure depressive symptoms among people with
epilepsy. People with epilepsy often experience symptoms due to
their condition or medication side-effects, such as memory
problems, decreased concentration, fatigue, and sleep distur-
bances,12,13 that overlap with depressive symptoms. The NDDI-E,
therefore, includes items assessing symptoms of depression that
are distinct from these overlapping symptoms.8 Friedman and
colleagues9 found that screening with the NDDI-E in an epilepsy
clinic increased the detection of depression signiﬁcantly.
Recently, the psychometric properties of depression scales have
been examined using contemporary measurement methodology,
such as item response theory and Rasch measurement models.
Compared to traditional measurement theory, a requirement of
Rasch models is that item calibrations are invariant across
samples; in other words, item calibrations for measuring depres-
sive symptoms are not sample dependent when good model-data
ﬁt is obtained.14–17 Therefore, items and persons can be calibrated
separately along a latent variable of depressive symptoms with the
person’s calibration reﬂecting the participant’s level of depressive
symptoms and the item’s calibration indicating the severity ofvier Ltd. All rights reserved.
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analysis to validate or improve the measurement properties of the
BDI and PHQ-918,19 or identify key items that can be used in shorter
screening scales.19,20 This work has been done in samples of
individuals with cancer,18 spinal cord injury,19,20 and coronary
heart disease.21 To our knowledge, Rasch analyses of depression
scales among people with epilepsy have not been conducted.
The primary purpose of this study was to use Rasch analyses in
order to evaluate and compare the psychometric properties of
three depression scales in a sample of people with epilepsy and
depression who participated in an intervention designed to reduce
depressive symptoms. Additionally, we examined differences in
item functioning based on time (pretest and posttest administra-
tions of the instruments). The following research questions were
addressed: (1) Do the items function as intended to deﬁne
measures of depression among people with epilepsy? and (2) Does
the intervention program (UPLIFT) affect how the items functioned
before and after the intervention?
2. Methods
2.1. Sample
This study is part of a larger study, funded by the Centers of
Disease Control and Prevention, that pilot tested the feasibility and
efﬁcacy of the Project UPLIFT (Using Practice and Learning to
Increase Favorable Thoughts) intervention.22 Following Institu-
tional Review Board approval at the researchers’ university,
participants were recruited from a hospital-based epilepsy clinic
from June 2007 through November 2008. All participants met the
following inclusion criteria: (1) diagnosis of epilepsy for at least
one year; (2) presence of depressive symptoms, as indicated by a
score greater than 13 on the Center for Epidemiological Studies
Depression scale (CES-D),5 and absence of severe depression, as
indicated by a score of less than 38 on the CES-D; (3) 21 years of age
or older; (4) English speaking; and (5) absence of prominent
cognitive impairment (e.g., delirium, dementia), as determined by
a score of 20 or above on the Telephone Mini Mental State
Examination.23 Individuals reporting active suicidal ideation were
ineligible to participate in the study. All participants provided
written informed consent.
2.2. Project UPLIFT
Project UPLIFT is a Cognitive Behavioral Therapy and mindful-
ness-based program for people with epilepsy and depression that
was delivered over the phone or internet to groups of about seven
participants. The program includes 8 weekly sessions that require
about an hour of the participants’ time per week. Each session
involves a check-in, instruction on the week’s topic, skill practice,
and group discussion. Phone group participants take part in a
weekly conference call and internet group participants interact
over a secure website. Program components were designed to
increase knowledge about depression and build skills to cope with
depressive symptoms. CBT activities include thought monitoring
and stopping, problem identiﬁcation, relaxation, and goal setting.
Mindfulness training involves mindful attention, meditations,
recognition of the impermanent nature of thoughts, and awareness
of pleasure. More detail on the Project UPLIFT program is provided
elsewhere.22,24
The pilot study was evaluated using a crossover design.25
Participants were randomized into two groups, initial treatment
group and waitlist control group, and then assessed at baseline.
The initial treatment group received the treatment following the
baseline assessment, during which time the waitlist condition
served as a treatment-as-usual (TAU) control group. Both groupswere assessed at an interim time point. The TAU waitlist group
then received the intervention. Finally, both groups were assessed
with a follow-up survey. For this analysis, we used the assessments
of both groups at pretest before the intervention (baseline for the
initial treatment group and interim assessment for the TAU waitlist
group) and posttest immediately after the intervention (interim
assessment for the initial treatment group and follow-up for the
TAU waitlist group).
For each assessment, trained interviewers read the instruments
to the participants over the phone. The surveys assessed depressive
symptoms, satisfaction with life, purpose in life, depression coping
self-efﬁcacy, quality of life, seizure severity, and demographic
information. Only the depression scales are examined here.
Participants received $25 for each assessment completed. In the
pilot study, Project UPLIFT was effective in reducing depressive
symptoms and increasing knowledge of depression and skills for
improving mood.22
2.3. Measures
2.3.1. Modiﬁed Beck Depression Inventory (mBDI)
The mBDI26 is a modiﬁed version of the BDI4 that includes a
positive feeling choice for each of the 21 items in addition to the
choices reﬂecting the negative aspects of each symptom. Thus,
each item in the mBDI includes 5 statements that range from 0
(positive experience) to 4 (severe negative experience).
2.3.2. Patient health questionnaire (PHQ-9)
The PHQ-96 is a 9-item scale that is based on the diagnostic
criteria for depression found in the American Psychological
Association’s Diagnostic and Statistical Manual (DSM-IV).27 The
items are rated on a 4-point scale of how often a person has been
bothered by each symptom in the past two weeks (0 being ‘‘never’’
and 3 being ‘‘nearly everyday’’).
2.3.3. Neurological disorders depression inventory for epilepsy
(NDDI-E)
The NDDI-E is a 6-item scale that measures symptoms of
depression that are distinct from symptoms that may result from
side-effects of anti-epileptic medication or having epilepsy, such as
memory problems, decreased concentration, fatigue, and sleep
disturbance.8 The items of the NDDI-E are measured on a 4-point
Likert scale reﬂecting how often a person experienced each
depressive symptom in the past two weeks (1 being ‘‘never’’ and 4
being ‘‘always or often’’).
2.4. Data analysis
Descriptive statistics were run in PASW Statistics 18. These
included demographic and scale descriptive statistics. Rasch
analyses were conducted using the Facets computer program
(Version 3.66.2). The Rasch measurement model is an item
response theory model that allows for an ordering of individuals
and items along a unidimensional latent variable. The probability
of a person endorsing a particular response option is based on the
person’s ability and the item difﬁculty.14 In this analysis, the latent
variable is level of depressive symptoms, the person’s ‘‘ability’’
refers to a participant’s level of depressive symptoms, and the item
difﬁculty indicates the severity of depressive symptoms repre-
sented by an item. Two sets of models were run. First, the BDI, PHQ-
9, and NDDI-E were analyzed separately using a rating scale model,
which is used when all items within an instrument have the same
number of response choices. Second, the items from all three scales
were entered into the same model; therefore a partial credit multi-
faceted Rasch model was used to take into account the different
number of response options for each scale. Running all of the items
Table 1
Demographic characteristics of Project UPLIFT participants.
Demographic
characteristics
Project UPLIFT participants
who completed pretest
(n = 44)
Age (years)
Range 21–59
Mean (SD) 34.86 (10.62)
Gender
Female, n (%) 36 (81.8)
Male, n (%) 8 (18.2)
Race
White, n (%) 33 (75.0)
Black, n (%) 11 (25.0)
Living situation
Alone, n (%) 4 (9.1)
With immediate family, n (%) 32 (72.7)
With friends, roommate, or partner, n (%) 7 (15.9)
Other, n (%) 1 (2.3)
Education level
High school or less, n (%) 13 (29.5)
Some college or currently in college, n (%) 13 (29.5)
Graduated college, n (%) 13 (29.5)
Graduate school or higher, n (%) 4 (9.1)
Other, n (%) 1 (2.3)
Marital status
Married, n (%) 17 (38.6)
Single, n (%) 20 (45.4)
Separated/divorced/widowed, n (%) 7 (16.0)
Employment status
Full-time, n (%) 13 (29.5)
Part-time, n (%) 5 (11.4)
Student, n (%) 3 (6.8)
Retired, n (%) 1 (2.3)
Do not work, n (%) 22 (50.0)
Seizures in the past 4 weeks
Yes, n (%) 28 (63.6)
SD, standard deviation; n, number of participants.
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the latent variable of depression for PWE. A facet was included for
each of the following: participants’ level of depressive symptoms,
difﬁculty in endorsing an item, and time (represented by the
pretest and posttest). The model can be written as follows:
Ln ½Pn jik=Pnki1 ¼ Qn  di  D j  tik
where Pnjik, the probability of participant n endorsing answer
choice k on an item i at time j; Pnki1, the probability of participant
n endorsing answer choice k1 on item i at time j; Qn, the level of
depressive symptoms for participant n; di, the difﬁculty of
endorsing item i; Dj, the time effect (pretest and posttest); tik,
the difﬁculty of endorsing answer choice k compared to answer
choice k1 on the items.
The Facets software calculates summary and ﬁt statistics
separately for each facet. The summary statistics provide an
estimated location on the latent variable, or level of depression, for
each component of a facet. The facet separation reliability
coefﬁcient indicates the overall separation of each facet. Person
separation is analogous to Cronbach’s a and is considered
acceptable at values over 0.7. Fit of the model to the data is
assessed by INFIT and OUTFIT statistics. Acceptable INFIT and
OUTFIT values for items with Likert scale response options fall
within the range of 0.6–1.4. Values above 1.4 indicate that the data
contains more variability than expected based on the model,
whereas values under 0.6 indicate less variance in the data than
expected based on the model.14
Differential Item Functioning (DIF) occurs when the location of
an item on the latent variable changes depending on person sub-
groups.28 In this study, DIF analysis was conducted to determine if
the items were ordered differently based on time (pretest and
posttest). DIF can be conceptualized as an interaction between
time and items (di*Dj). This means that item location is dependent
on time. Part of the DIF analysis involves t-tests comparing the
average score on each item at pretest and posttest.
3. Results
3.1. Sample
A total of 53 people were enrolled in the Project UPLIFT pilot
study and randomized to the initial UPLIFT treatment condition or
the TAU waitlist condition. This study utilized a sample size of 44
individuals (23 in the treatment and 21 in the TAU waitlist groups)
who completed the assessment prior to participating in the
intervention. Of these 44 individuals, 38 people (19 in each of the
treatment and TAU waitlist groups) completed the assessment
immediately post-intervention. The majority of the participants
were female, white, single, lived with family, completed at least
some college, and did not work (see Table 1). About two-thirds of
the sample had experienced a seizure in the past month.
3.2. Descriptive statistics
Descriptive statistics for the mBDI, PHQ-9, NDDI-E, and
combined scales are shown in Table 2. As expected, the mean
depressive symptoms for each scale decreased from pretest to
posttest. The effect sizes, in logits, are 0.37 for the mBDI, 0.17 for
the PHQ-9, 0.29 for the NDDI-E, and 0.33 for the combined scales.
The Rasch measures accounted for 27.94% of the variance of the
mBDI scale, 56.27% for the NDDI-E, 46.08% for the PHQ-9, and
43.53% for all the scale items combined. Values above 20% are
considered to reﬂect an acceptable unidimensional scale for Rasch
analysis.293.3. Variable map and Rasch analysis
Fig. 1 displays the variable map representing the calibration of
participants and items, combining the pretest and posttest result.
The ﬁrst column of Fig. 1 shows the logit scale which serves as the
ruler along which the facets (persons and items) are calibrated so
that they can be placed on the same scale. The second column
displays the participants’ level of depression. More depressed
individuals appear at the top of the variable map while individuals
with lower levels of depression appear at the bottom. The third
column displays the location of all of the depression items from the
three scales combined. The items range from about 1.75 to 1.25
logits on the latent variable, with the majority clustered around
0.5 to 1.00 logits. The fourth through sixth columns show the
locations of the depression items from each of the three scales
separately. Each item is identiﬁed by the ﬁrst letter of the scale it is
from and the item number (ex. B1 is the ﬁrst item from the mBDI
scale). The item that was hardest to endorse, indicating that the
respondent had to experience a high level depressive symptoms in
order to say they felt this way, was the item on the PHQ-9 assessing
how often a participant had ‘‘thoughts that you would be better off
dead or of hurting yourself in some way.’’ The easiest item to
endorse was the NDDI-E item assessing the frequency that
individuals felt frustrated. The mBDI tended to be clustered
between 0.5 and 0.5 logits on the latent variable, while the items
of the PHQ-9 and NDDI-E showed a greater spread. Almost all of the
NDDI-E items were under zero logits on the latent variable. The
exception is the item ‘‘I’d be better off dead,’’ which is located much
higher on the latent variable, indicating that it is difﬁcult to
endorse.
The variable map (Fig. 1) is useful for comparing the spread of
the items compared to the individuals, which indicates how well
Table 2
Scale descriptive statistics.
Number of items Possible score range Mean (SD) Effect size in logits % Variance explained
Pretest Posttest
mBDI 21 0–84 26.36 (11.21) 20.84 (10.15) 0.37 27.94
PHQ-9 9 0–27 9.84 (6.70) 8.34 (5.95) 0.17 46.08
NDDI-E 6 6–24 14.64 (4.09) 12.97 (4.00) 0.29 56.27
Combined 36 6–135 50.84 (19.90) 42.16 (17.70) 0.33 43.53
SD, standard deviation; mBDI, modiﬁed Beck Depression Inventory; PHQ, Patient Health Questionnaire; NDDI-E, Neurological Disorders Depression Inventory for Epilepsy.
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Table 3
FACETS summary statistics.
Measures Inﬁt Outﬁt Reliability of separation x2 statistic Degrees of freedom
Mean SD n Mean SD Mean SD
mBDI
Persons 0.84 0.65 44 1.04 0.42 1.02 0.38 0.90 406.1* 43
Items 0 0.33 21 1.00 0.18 1.02 0.23 0.84 125.7* 20
Time 0 0.26 2 1.02 0.08 1.01 0.09 0.98 44.7* 1
PHQ-9
Persons 0.91 1.30 44 1.02 0.50 0.98 0.56 0.84 263.9* 43
Items 0 0.70 9 1.01 0.16 0.99 0.24 0.95 113.4* 8
Time 0 0.24 2 1.00 0.07 0.99 0.07 0.92 12.2* 1
NDDI-E
Persons 0.38 1.16 44 1.01 0.64 0.99 0.76 0.84 222.9* 43
Items 0 1.06 6 1.00 0.18 0.98 0.21 0.98 174.2* 5
Time 0 0.41 2 0.99 0.08 0.97 0.13 0.95 21.6* 1
Combined
Persons 0.71 0.68 44 1.03 0.38 1.00 0.37 0.95 709.5* 43
Items 0 0.53 36 1.00 0.16 1.00 0.26 0.93 431.1* 35
Time 0 0.26 2 1.01 0.06 0.99 0.06 0.99 69.7* 1
SD, standard deviation; n, number of participants; mBDI, modiﬁed Beck Depression Inventory; PHQ, Patient Health Questionnaire; NDDI-E, Neurological Disorders Depression
Inventory for Epilepsy.
* p < 0.05.
E.R. Walker et al. / Seizure 21 (2012) 437–443 441the items and the sample are matched. Looking at the combined
scales, there is good overall targeting between the items and the
persons as denoted by the overlap in spread. The individuals do not
overlap with the items that indicate more severe depression, such
as those related to suicide. This gap is to be expected since persons
with severe depression or suicidal ideation were not eligible for
this study. Comparing the individual scales, some scales ﬁll in the
gaps for others. The items of the mBDI are clustered rather closely
together and match fairly well to the persons. The PHQ-9 has a
wider range and is a better match for the sample. The NDDI-E also
has a wide range; however, due to the relatively low number of
items, there are several gaps. The mBDI and PHQ-9 help to ﬁll in the
top gap and the PHQ-9 helps somewhat to ﬁll in the lower gap.
The summary statistics for persons, items, and time are
presented in Table 3. Persons are the focus of the measurement-6
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Out of 44 participants, 35 have the expected OUTFIT mean
square statistic ranging between 0.6 and 1.2. This indicates
acceptable model-data ﬁt for these 35 PWEs. Four participants
have an OUTFIT mean statistic below 0.6, while ﬁve have OUTFIT
statistic higher than 1.2. To illustrate the usefulness of residual
analyses for examining OUTFIT statistics, two participants were
selected, one with an elevated OUTFIT statistic, and one with an
expected OUTFIT statistic. The data for Participants 19 and 130 are
shown in Fig. 2. Participant 19 had a higher than expected OUTFIT
mean statistic (OUTFIT = 1.83), indicating greater than expected
variability in the responses. Participant 130 (OUTFIT = 0.98) had an
expected degree of consistency among the responses. Consistent
with their OUTFIT scores, the plot for Participant 19 shows much
more variability than the plot for Participant 130.
3.5. Differential item functioning
An analysis of Differential Item Functioning, the interaction
between items and time, indicated that the items functioned
similarly at pretest and posttest. Almost all of the posttest items
are lower on the latent variable compared to the pretest items.
Three items, however, functioned differently than expected at
posttest. Compared to the mean depression score on pretest,
participants had a signiﬁcantly higher mean depression score for
the following three items at posttest: mBDI18 (appetite), mBDI21
(sex drive), and PHQ3 (‘‘Trouble falling or staying asleep, or
sleeping too much’’). Additionally, the mean depression score for
mBDI11 (irritation) was signiﬁcantly lower at posttest than
expected.
4. Discussion
The purpose of this study was to examine how the items from
three depression scales functioned, using data from an interven-
tion study that has been shown to effectively reduce depressive
symptoms among people with epilepsy. Additionally, we were
interested in assessing differences in item functioning from pretest
to posttest.
Addressing the ﬁrst research question, the variable map and
other Rasch measurement model analyses indicate that the three
depression scales functioned as intended among this sample. The
variable map provides a useful visual for comparing how the three
depression scales functioned for people with epilepsy and
depression. Combining all of the items from each scale proved
to be quite informative in determining how well each scale was
matched with the sample on the latent variable of depression.
Overall, the scales were well targeted for the sample, with items
from different scales ﬁlling in gaps in the other scales.
None of the scales covered the full range of depression on their
own, however. This suggests that choosing multiple depression
scales for studies may be important to capture the full range of the
latent variable for people with epilepsy. This is particularly true for
the NDDI-E, which has a gap in the middle range of depression. The
NDDI-E is designed to be a brief screening tool;8 therefore
following up with another depression scale or a psychiatric
structured interview may worthwhile.
Unlike traditional measurement analyses, the Rasch models
allowed us to examine individuals as well as the overall group.
Person ﬁt analyses provide a framework for examining in detail
unexpected item responses within each of the depression scales
that may be useful in obtaining a deeper understanding of how
effective the intervention was in changing particular self-reported
behaviors. The overall effect of the UPLIFT program was signiﬁcant
for the group from pretest to posttest, and the individual levelanalyses provided the opportunity for an in-depth exploration of
each participant’s responses on each item. Additional qualitative
analyses can be conducted with individuals exhibiting unusual
response patterns on the three depression scales.
The Rasch analysis also allowed for an examination of how
the items functioned at pretest and posttest, which demon-
strates its usefulness in examining change over time for
intervention trials. The results support the effectiveness of the
Project UPLIFT program in reducing depressive symptoms
among people with epilepsy. However, the item order was
not completely invariant over time. Three items, related to
appetite, sex drive, and sleep, had higher mean depression
scores at posttest compared to pretest. These symptoms could
be attributed to side-effects from antiepileptic medications30–32
and, if so, would not necessarily be impacted by the interven-
tion. The scores for these items, however, are not expected to
increase; the higher mean score at posttest may suggest that
people were not giving ‘‘social desirable’’ responses and telling
us everything was better. In contrast, the other mood related
items did decrease from pretest to posttest. These symptoms
may be more amenable to change from a mindfulness-based
intervention, such as Project UPLIFT. Mindfulness teaches
individuals to become aware of and acknowledge their thoughts,
but release attachments to thoughts and suffering.33 Therefore,
mindfulness training may allow participants to more readily let
go of feelings of irritation and worthlessness.
4.1. Limitations
One limitation of this study is the small sample size, which is
common for intervention pilot studies. Therefore, the results,
particularly the DIF comparisons of individual items, should be
interpreted with caution. While Rasch analyses are often
conducted on large samples, utilizing a small sample enabled
us to look in more detail at the characteristics of the individuals
involved in the program. A strength of Rasch analyses is that
they are sample-free; however as an ideal-type model, the
application of these results to another sample would represent a
hypothesis. Therefore, given the small sample size, replication in
a larger sample would be useful. A second limitation is that
participants were screened using the CES-D, which is not
included in this analysis because it was not administered at the
same time as the other three depression scales. Finally, the
sample was drawn from one tertiary epilepsy clinic; therefore
the results may not be generalizable to the broader population
of people with epilepsy.
5. Conclusion
This study demonstrated how Rasch analyses of three
depression scales can provide insight into the depressive
symptoms experienced by people with epilepsy. Additionally,
it showed the usefulness in using Rasch analysis to examine how
an intervention affects particular symptoms of depression.
Rasch analysis would be useful in future research to explore
how to ﬁll in where scales have gaps in measuring depression –
either through additional items or additional scales. The
depression scales could also be compared to a psychiatric
structured interview to see if they perform in a similar manner.
Another area of potential inquiry is to utilize Rasch analyses and
qualitative methods to examine the reasons for differences
between people in how they responded to the individual items.
For people with epilepsy in particular, Rasch analyses could be
useful in further exploration of the symptoms that overlap
between depression and epilepsy.
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